Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

commercial and other potential of APD125 and other of Arena's drug candidates; the possibility of APD125 to be a non-scheduled treatment; the relevance of indicators of sleep maintenance; the advancement and content of Arena's pipeline; and other statements about Arena's vision, outlook, strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out- licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward- looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partne
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... The U.S. Food and Drug Administration,s (FDA) ... decided today that it could not recommend approval ... the currently available data (13-3); but, voted unanimously ... a reader training program that demonstrates reader accuracy ...
... Medical Simulation Corporation (MSC) will highlight a ... providers at the 2011 International Meeting on Simulation ... MSC,s full-service simulation training and education services are ... all healthcare providers. MSC,s complete line of equipment ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare 2
(Date:9/22/2014)... On Tuesday, September 16th, 2014, at 8:00 p.m. ... “KC After Dark.” Hosted by top WRNW1 host, ... every Tuesday at 8:00 p.m. EST. WRNW1 had a promotion ... and because of the amazing turnout for their first show, ... 500 callers. , During this comical, yet professional show, ...
(Date:9/22/2014)... September 22, 2014 The Philadelphia 100, ... Greater Philadelphia region each year, is considered a hallmark ... manufacturer MK Precision is proud to announce it has ... MK Precision will attend the Philadelphia 100 ... the premiere business events of the year, as well ...
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... Amy Norton HealthDay Reporter ... may fare better when newborn intensive care units (NICU) set ... infants, a new study finds. Researchers at one children,s ... and were less distressed when their NICU switched from the ... findings, published online Sept. 22 in the journal Pediatrics ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2
... The Autism Research Institute states that many of those ... appropriately diagnosed and treated may result in marked improvementATLANTA, ... every 20 seconds in the US. Autism is ... AIDS combined. The Federal Centers for Disease Control ...
... SANTA MONICA, Calif., April 6 Cord Blood America, Inc. ... preservation company ( http://www.cordblood-america.com ) ... to families nationwide and internationally, is pleased to announce that ... long term debt by approximately $750,000, or 12 percent. ...
... place in line at local emergency departments and ... has selected Trevelino/Keller Communications Group, Inc., one of ... launch the company nationally and build out its ... Alabama and Florida -- as it pursues national ...
... a systemic disease or an autoimmune disorder in which the ... of cells called the synovium that lines and lubricates the ... and crippling stiffness, particularly of the hands and feet. It ... mobility and quality of life. RA cannot be confirmed or ...
... solutions provider, is pleased to announce that its entire suite of ... , ... Charlotte, NC (PRWEB) April 6, 2009 -- IQMax, ... that its entire suite of healthcare solutions is available on Blackberry® ...
... high blood pressure and heart disease during a clinical trial for osteoarthritis. ... ... Company, a Bendigo based company who manufactures a topical pain relief lotion ... trial for their flagship product, Elmore Oil., , ,The trial was headed ...
Cached Medicine News:Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 3Health News:IQMax Delivers Healthcare Solutions to Blackberry Devices 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
...
Medicine Products: